The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Northwestern University
Consulting or Advisory Role - American cancer society; Bionest Partner; Cancer Expert Now; Decision Resources; Harborside Press; Health Advances; Imedex; Lynx Group; NCCN/AstraZeneca; Patient Resource; PreCisCa; Research to practice; Shanghai International Colorectal Cancer Symposium; The Dedham Group; Total Health Conferencing
Research Funding - Lexicon; PrECOG
Travel, Accommodations, Expenses - unknown
Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
 
Jean-Baptiste Bachet
Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; Pierre Fabre; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Merck Serono; Pierre Fabre; SERVIER
Travel, Accommodations, Expenses - Bayer; Roche; Sanofi; SERVIER
 
Benoist Chibaudel
Honoraria - Bayer; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - BeiGene; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Merck; MSD; Roche; Sanofi
 
Manel Rakez
No Relationships to Disclose
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Taiho Pharmaceutical
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Niall C. Tebbutt
Honoraria - Bristol-Myers Squibb; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Daniel G. Haller
Speakers' Bureau - Amgen; Exelixis; Lilly; Taiho Pharmaceutical
 
J. Randolph Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Acrotech Biopharma; Astellas Pharma; Corcept Therapeutics; Gilead Sciences; Merck; Regenacy Pharmaceuticals
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Forty Seven (Inst); Gritstone Bio (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Advaxis; Amgen; Lilly
 
Robert J. Mayer
Consulting or Advisory Role - Bayer
 
Stuart M. Lichtman
Consulting or Advisory Role - Magellan Health; Remedy One
 
Al Benson
No Relationships to Disclose
 
Alberto F. Sobrero
Stock and Other Ownership Interests - Bayer
Consulting or Advisory Role - Amgen; Bayer; Celgene; Menarini; Merck Serono; Roche; Sanofi; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche; Takeda
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Seagen; Servier; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose